Shuttle Pharmaceuticals Holdings, Inc.
SHPH evidence brief
What we can confirm
- BioSniper Score:
- 9.9 / 10
- Market Cap:
- $2.1M
What it means
What to watch
Prepared research question
What matters most for SHPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SHPH
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a discovery-stage specialty pharmaceutical company that, after discontinuing its clinical programs, pivoted to an AI-driven drug discovery platform via the acquisition of Molecule.ai in November 2025.
Key risk: Very low cash reserves
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$2.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a discovery-stage specialty pharmaceutical company that, after discontinuing its clinical programs, pivoted to an AI-driven drug discovery platform via the acquisition of Molecule.ai in November 2025.
- Acquired substantially all assets of Molecule.ai, an AI-driven molecular discovery platform, on November 21, 2025 [sec_mda · as of 2026-09-24].
- Cash and equivalents were $0.1M as of 2026-06-30 [sec]; net income was -$3.1M for the period ending 2026-06-30 [sec].
- Shareholders' equity was $19.2M as of 2026-06-30 [sec].
- The company had a working capital deficit of $7,463,980 as of December 31, 2025 [sec_mda · as of 2026-03-31].
- Patient enrollment in the Phase 2 trial of ropidoxuridine for glioblastoma reached 63% as of August 2025 [news · published 2025-08-15].
What works
- The Molecule.ai platform is designed to accelerate drug discovery iteration cycles while preserving scientific reproducibility and traceability [sec_mda · as of 2026-03-31].
- The company launched an upgraded Autonomous Self Reasoning AI Agent for scientific workflows in March 2026, expanding therapeutic discovery capabilities [news · published 2026-03-26].
- Shareholders' equity of $19.2M as of 2026-06-30 provides a capital base for ongoing operations [sec].
What to weigh
- Cash and equivalents were only $0.1M as of 2026-06-30, indicating very limited liquidity [sec].
- The company reported a net loss of -$3.1M for the period ending 2026-06-30 [sec].
- Working capital deficit was $7,463,980 as of December 31, 2025, reflecting negative working capital [sec_mda · as of 2026-03-31].
- The company is still evaluating business impacts from discontinuing clinical trials and the Molecule.ai acquisition, creating uncertainty [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
Acquisition of Molecule.ai occurred on November 21, 2025
“November 21, 2025, we acquired substantially all of the assets of Molecule.ai”
SEC MD&A · September 24, 2026
Phase 2 trial enrollment reached 63%
“Patient enrollment in the Company’s Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma reached 63%”
News · August 15, 2025
Catalyst timeline
- 2024-09-02 · Phase 2 Study of Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in Patients With Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter — This Phase 2 trial start date is from the catalyst block; enrollment was at 63% as of August 2025.
Risks & what to watch (4)›
Key risks
- Very low cash reserves — Cash of $0.1M as of 2026-06-30 may not sustain operations for long without additional funding [sec].
- Negative working capital — Working capital deficit of $7.5M as of Dec 31, 2025 indicates current liabilities exceed current assets [sec_mda · as of 2026-03-31].
- Uncertainty from strategic pivot — Company still evaluating business impacts from discontinuing clinical trials and acquiring Molecule.ai [sec_mda · as of 2026-03-31].
- No approved products or revenue — Company is discovery-stage with no marketed products; net loss of $3.1M in latest period [sec].
What to watch
- Progress of the Phase 2 glioblastoma trial for ropidoxuridine, which had 63% enrollment as of August 2025 [news · published 2025-08-15].
- Adoption and revenue generation from the Molecule.ai platform after the March 2026 AI agent upgrade [news · published 2026-03-26].
- Ability to raise additional capital given low cash reserves of $0.1M as of 2026-06-30 [sec].
- Any further updates on the company's evaluation of the clinical trial discontinuation and acquisition impacts [sec_mda · as of 2026-03-31].
Sources: Catalysts · Competitor trials · News · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Shuttle Pharmaceuticals Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Shuttle Pharmaceuticals Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.19 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
6 buys · 5 sells (180d)
Financials
Short Interest
as of Apr 30, 2026- % of float
- 1.3%
- Days to cover
- 0.3
- Shares short
- 71,193
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SHPH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Shuttle Pharmaceuticals Holdings, Inc.?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a discovery-stage specialty pharmaceutical company that, after discontinuing its clinical programs, pivoted to an AI-driven drug discovery platform via the acquisition of Molecule.ai in November 2025.
Who is the CEO of Shuttle Pharmaceuticals Holdings, Inc.?
Mr. Christopher Robert Cooper BBA, M.B.A. is the chief executive officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH).
Where is Shuttle Pharmaceuticals Holdings, Inc. headquartered?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is headquartered in Gaithersburg, MD, United States.
What therapeutic areas does Shuttle Pharmaceuticals Holdings, Inc. focus on?
Shuttle Pharmaceuticals Holdings, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.